laitimes

Lilan's new product was approved, and it is expected to increase revenue by 600 million to 700 million US dollars

Lilan's new product was approved, and it is expected to increase revenue by 600 million to 700 million US dollars

After meeting the market development trend and the urgent needs of users, Lilan Animal Protection may usher in a longer-term and faster development trend.

Recently, Elanco, the world's leading animal protection company, announced that its product Zenrelia™ (ilunocitinib tablets, transliterated as ibrutinib tablets) was officially approved and marketed by the United States Food and Drug Administration (FDA), which will provide safer and more effective product solutions for canine skin diseases.

According to the official introduction, the product is a safe, efficient and convenient oral JAK inhibitor new drug. In terms of product efficacy, the product is used once daily to control itching (pruritus) associated with atopic dermatitis and atopic dermatitis (AD) in dogs at least 12 months of age.

In addition, clinical trials have shown that Zerelia™ is able to achieve clinical remission of pruritus in 77% of cases. It has surpassed the 53% success rate of the existing JAK inhibitor Apoquel® (generic name: olatinib maleate tablets).

Lilan's new product was approved, and it is expected to increase revenue by 600 million to 700 million US dollars

Currently, Zenrelia™ is only available with a prescription from a licensed veterinarian. Because veterinary expertise is required to determine if the medicine is suitable for the pet owner's pet and to monitor the patient for possible infections or other potential side effects while taking the drug.

However, for Zenrelia itself, the approval of Zenrelia™ will further enhance the existing product portfolio, providing veterinarians and pets with a more diversified product selection to improve the health and quality of life of dogs with AD.

Lilan's new product was approved, and it is expected to increase revenue by 600 million to 700 million US dollars

Talking about the strategic significance and goal of launching this series of products, Lilan Animal Health also said that diseases such as atopic dermatitis and atopic dermatitis are one of the diseases that are very common and high incidence in dogs. Currently, about 17 million dogs in the United States suffer from allergic-related skin diseases, including atopic dermatitis, food allergies or flea sensitivities. Of these, 60% of pet owners said they had tried to treat itching in their dogs, but nothing worked.

Based on such urgent user needs and pain points, Lilan Animal Health decided to deepen this category and significantly improve the health of pets through products, in order to bring more effective solutions for pet welfare.

Lilan's new product was approved, and it is expected to increase revenue by 600 million to 700 million US dollars

This once again verifies the long-term product development and innovation strategy of Lilan Animal Protection. Interestingly, at the same time as the official launch of Zenrelia™, another blockbuster new product of Lilan Animal Protection, the Credelio Quattro insect repellent series, was also ready to be launched.

According to the official disclosure of Lilan Animal Protection, the Credelio Quattro deworming series is a broad-spectrum oral anthelmintic drug for fleas, ticks and internal parasites. At present, the effectiveness and safety verification of the product has been completed. Final FDA approval is expected in the fourth quarter of 2024, with the product available in the first quarter of 2025.

In this regard, Jeff Simmons, President and CEO of Aleblue Animal Protection, also previously said: "The FDA's review of Bovaer and the FDA's final submission to Zenrelia put us on track to achieve the expected revenue contribution of $600 million to $700 million in new business in 2025. At the same time, Lilan Animal Health is still full of confidence in the great potential of the Chinese market. ”

Lilan's new product was approved, and it is expected to increase revenue by 600 million to 700 million US dollars

Based on the dynamics of Lilan Animal Health in the global and Chinese markets, the pet industry observes that with the continuous advancement of Lilan Animal Protection's product R&D and innovation strategy, it will also rely on the continuous expansion of the product matrix to gain a larger market share in the pet business segment and more loyal user trust.

For example, in the first half of this year, with the continuous penetration of product mentality, Lilan Animal Protection has also achieved faster growth and deeper channel coverage, and laid a solid foundation for subsequent growth.

As for the future dynamics of Lilan animal protection and pet drug market, the pet industry observation will continue to pay attention. For those who are interested in this topic, please leave a message in the comment area below to discuss, or add a small editor to communicate on WeChat.